A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif(R) (IFN-Beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis.

Trial Profile

A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif(R) (IFN-Beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 29 Mar 2015 Last checked against ClinicalTrials.gov record.
    • 08 Jul 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 14 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top